CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 160 filers reported holding CRISPR THERAPEUTICS AG in Q4 2018. The put-call ratio across all filers is 1.91 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $43,337,000 | -27.8% | 518,146 | -36.5% | 0.01% | -30.8% |
| Q2 2020 | $59,997,000 | +99.6% | 816,395 | +15.2% | 0.01% | +62.5% |
| Q1 2020 | $30,066,000 | -29.4% | 708,952 | +1.4% | 0.01% | -11.1% |
| Q4 2019 | $42,593,000 | +6.0% | 699,336 | -28.6% | 0.01% | 0.0% |
| Q3 2019 | $40,165,000 | -33.2% | 979,892 | -23.3% | 0.01% | -30.8% |
| Q2 2019 | $60,151,000 | +15.8% | 1,277,089 | -12.2% | 0.01% | +8.3% |
| Q1 2019 | $51,959,000 | +116.1% | 1,454,630 | +72.9% | 0.01% | +100.0% |
| Q4 2018 | $24,040,000 | -29.8% | 841,438 | +8.9% | 0.01% | -14.3% |
| Q3 2018 | $34,260,000 | -42.4% | 772,473 | -23.6% | 0.01% | -46.2% |
| Q2 2018 | $59,430,000 | +41.4% | 1,011,415 | +10.0% | 0.01% | +30.0% |
| Q1 2018 | $42,031,000 | +158.3% | 919,514 | +23.0% | 0.01% | +150.0% |
| Q1 2017 | $16,272,000 | +8.4% | 747,450 | +0.4% | 0.00% | 0.0% |
| Q4 2016 | $15,007,000 | – | 744,380 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
| Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
| EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
| NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
| ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
| NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
| Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
| Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |